Nivegacetor - Roche
Alternative Names: RG-6289Latest Information Update: 13 Aug 2025
At a glance
- Originator Roche
- Class Antidementias; Azabicyclo compounds; Bridged bicyclo compounds; Ethers; Fluorobenzenes; Methyl ethers; Pyridazines; Pyrrolidines; Triazoles
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
Most Recent Events
- 13 Aug 2025 Chemical structure information added.
- 14 Nov 2024 Banner Alzheimers Institute and Neurosciences Group at the University of Antioquia (GNA) in Medellin plans a clinical trial for Alzheimer's-disease (Monotherapy, Prevention, In adults), in fall 2025 (IV) (NCT06996730)
- 14 Aug 2024 Phase-II clinical trials in Alzheimer's disease (unspecified route) (Roche pipeline, August 2024)